Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Leukemia, Myeloid, Acute
  • Oligonucleotides
  • X-Linked Inhibitor of Apoptosis Protein

abstract

  • The addition of AEG35156 to reinduction chemotherapy was well tolerated but did not improve rates of remission. Therefore alternative therapeutic strategies should be explored in patients with AML refractory to induction chemotherapy.

publication date

  • October 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.clml.2011.03.033

PubMed ID

  • 21729686

Additional Document Info

start page

  • 433

end page

  • 8

volume

  • 11

number

  • 5